New ESMO guidelines for clinical practice in metastatic colorectal cancer – commentary on changes in systemic therapy
Klinicka onkologie · 2023
DOI: 10.48095/ccko2023473 ↗Kurz gefasst
Leitlinie in der Zeitschrift Klinicka onkologie, 2023. Verfasst von I Kiss. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Commentary on the newly released European Society for Medical Oncology (ESMO) guidelines for the diagnosis and treatment of metastatic colorectal cancer (mCRC). After 6 years, individual chapters have been updated, from molecular tumor testing to diagnostic and treatment procedures to the implementation of newly registered medicinal products. The authors highlight the most important changes in the guidelines. Awareness of possible new treatments for mCRC is important to determine the treatment strategy for patients with mCRC. In this commentary, we focus primarily on the status of systemic treatment in unresectable disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Zitieren
APA
Kiss, I. (2023). New ESMO guidelines for clinical practice in metastatic colorectal cancer – commentary on changes in systemic therapy. Klinicka onkologie. https://doi.org/10.48095/ccko2023473
Vancouver
Kiss I. New ESMO guidelines for clinical practice in metastatic colorectal cancer – commentary on changes in systemic therapy. Klinicka onkologie. 2023. doi:10.48095/ccko2023473
BibTeX
@article{Kiss2023,
author = {Kiss, I},
title = {New ESMO guidelines for clinical practice in metastatic colorectal cancer – commentary on changes in systemic therapy},
journal = {Klinicka onkologie},
year = {2023},
doi = {10.48095/ccko2023473}
}
EUVIMED